Ropes & Gray Represents CAMP4 Therapeutics in $100 Million Series B Financing
Ropes & Gray represented CAMP4 Therapeutics in a $100 million Series B financing. CAMP4 is pioneering a novel class of RNA-based therapies designed to dial up the output of genes to treat genetic diseases. The company will use the funds to advance its lead programs into the clinic, with an initial focus on a severe form of epilepsy and life-threatening liver diseases.
The financing was announced on July 20. Enavate Sciences, a portfolio company created by Patient Square Capital, led the funding round.
The Ropes & Gray team was led by life sciences partner Marc Rubenstein and associates Joe Muller and Austin Bohn.